A U.S. Food and Drug Administration advisory panel has voted against approving Johnson & Johnson’s blood thinner Xarelto for prevention of blood clots in people with acute coronary syndrome.
According to U.S. News and World Report, the 6-to-4 decision came as a surprise because an FDA briefing document filed Monday in advance of the ruling gave the drug a favorable assessment.
But panel members reportedly said company studies did not provide enough ...
continue reading...